Synergistically Enhanced in-Vitro Cytotoxicity and Overall Survival in NSG Xenografts Against Burkitt Lymphoma (BL) and Primary Mediastinal Large B Cell Lymphoma (PMBL) by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) Alone or In-Combination With Obinutuzumab

Authors

Aradhana Awasthi
Dina Edani, New York Medical College
Janet Ayello, New York Medical CollegeFollow
Christian Klein
Mitchell S. Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

9-2018

Journal Title

British Journal of Haematology

Department

Pediatrics

Second Department

Health Behavior and Community Health

Recommended Citation

Awasthi, A., Edani, D., Ayello, J., Klein, C., & Cairo, M. S. (2018). Synergistically Enhanced in-Vitro Cytotoxicity and Overall Survival in NSG Xenografts Against Burkitt Lymphoma (BL) and Primary Mediastinal Large B Cell Lymphoma (PMBL) by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) Alone or In-Combination With Obinutuzumab. British Journal of Haematology, 182 (Suppl. 1), 47-48. https://doi.org/10.1111/bjh.15536